Clinical Trial

Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes that express homogeneous TCR recognizing KRN7000 which was up-regulated by many kinds of cancer cells. PD-1+CD8+T cells of patients with advanced tumor are most likely tumor-specified. Our hypothesis is that immunotherapy strategy of infusion of iNKT cells and PD-1+CD8+T cells may decrease the tumor burden and improve overall survival. The purpose of this study is to assess the safety and efficacy of treatment of patients with advanced solid tumor by infusing of iNKT cells and PD-1+CD8+T cells.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-03-22; most recent amendment 2025-06-29.
Status change: Active, Not Recruiting → Recruiting 2025-06-29
Status change: Recruiting → Active, Not Recruiting 2022-05-06
Trial Details
NCT Number NCT03093688
Lead Sponsor Shanghai Public Health Clinical Center
Conditions Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreas Cancer, Hepatocellular Carcinoma, Gastric Cancer, Renal Cell Carcinoma
Enrollment 40 participants
Start Date 2017-03-01
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-02